Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
295.52 USD | -1.55% |
|
+0.35% | -16.25% |
06-30 | United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says | MT |
06-30 | UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating | MT |
Official Publications
No official publication found
- Stock Market
- Equities
- UTHR Stock
- News United Therapeutics Corporation
- Official Publications
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition